The future of varicella vaccine.
Based on conservative figures, an estimated 60 million varicella-zoster cases occur annually worldwide, highlighting the global significance of this disease. The development of a viable varicella vaccine, therefore, raises important questions as to the indications for its use in normal children, normal seropositive and seronegative adults, and immunocompromised patients. A review of the available data addresses the potential future role of the varicella vaccine in these groups.
D002644:Chickenpox / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D019433:Chickenpox Vaccine; D006562:Herpes Zoster / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D007223:Infant; D014611:Vaccination / Q000639:trends; D014765:Viral Vaccines
D019433:Chickenpox Vaccine; D014765:Viral Vaccines